Sabinsa Granted Patent for Forskolin Process
The New Zealand Patent Office has granted a patent to Sabinsa for processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin. NZ Patent No: 568652 'Commercial Process for Making Forskolin and its Derivatives' will be in force until February 2, 2027.
The New Zealand Patent Office has granted a patent to Sabinsa for processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin.
NZ Patent No: 568652 'Commercial Process for Making Forskolin and its Derivatives'ÃÂ will be in force until February 2, 2027.
This most recent patent is #63 in Sabinsa...s worldwide Intellectual Property portfolio. Additionally, Sabinsa has more than 50 pending patent applications worldwide. This patent furthers Sabinsa...s ability to protect their Intellectual Property as they make inroads into Oceania. The company recently received Product Information (PI) numbers for ForsLean 10% and 20% from Australia...s TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing, opening the way for ForsLean to enter the Australian market.
Press release by Sabinsa
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
